Data

#Clinical trials #Covid-19 #Data #Funding #Therapeutics

Appili Therapeutics secures $3.5 million in funding

Appili Therapeutics has entered into a $3.5 million convertible security funding agreement with Lind Global Fund. The company intends to use the funding to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase II study in 2022. It will also support the operations… Read More

#News

#Biologics #Biology #Data #Genetics / genomics #RNA #Therapeutics

Starting line: focus on Canadian start-ups

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion #Start-up Zone

#Biotechnology #Clinical trials #Data #Microbiology #Pharmaceuticals

Cardiac patients receiving nasal gel showed reduction of S. aureus

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has released data from its recent Phase IIb clinical trial. In March 2021, the company announced that this study had met its primary endpoint, demonstrating a reduction of 2.5 log… Read More

#News

#Data #Drug discovery #Drug innovation #Life sciences

Paradigm4 launches multi-omics app for advanced cross-study analysis

Paradigm4 has launched Reveal: Multi-Omics, an app which allows researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across integrated public reference and proprietary datasets. It is built on top of Paradigm4’s SciDB analytics platform, designed for rapid data slicing that enables scientific data modelling,… Read More

#News

#Awards #Clinical trials #Covid-19 #Data #Drug discovery #Immunology / Virology & Vaccines

Breakthrough Therapy Designation for single-shot chikungunya vaccine

Vaccine development company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA). Breakthrough Therapy Designation intends to facilitate and expedite development and review of new drugs for serious or life-threatening conditions where preliminary clinical data demonstrates that… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Covid-19 #Data #Research

Industry report: Digital innovation and clinical trials

In the aftermath of Covid-19, ambitious strategies for digital transformation are seen as a wise investment as life sciences organisations upgrade their capacities for managing clinical trials and the scientific and regulatory data they generate. This is the key overall finding of the second annual TMF Futures survey of over… Read More

#Intelligence #Market Reports

#Alzheimer's #Data #Drug delivery #Drug design #Exscientia #Pharma

The role of AI in Alzheimer’s drug candidate design

Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects… Read More

#Exclusive Content #News

#Data #Data science #Flow Cytometry #Pharma #Phenomics

Are scalable data science platforms the way forward?

Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.  As researchers approach the practical limits of flow cytometry and are challenged to simultaneously explore the thousands of… Read More

#Editor's Choice #Exclusive Content #News

#AI #Augmented Chemistry #Data #Drug discovery #Pharma

Optibrium publishes study on AI applications in pharma

Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets… Read More

#News

#Biotechnology #Clinical trials #Data

Formedix and CDISC join forces to accelerate clinical trial set-up

Formedix, a provider of clinical trial software solutions, has collaborated with CDISC, the global clinical research data standards development organisation, to create a novel portal providing free access to ready-to-use, CDASH-compliant, annotated electronic case report forms (eCRFs). As part of this partnership, Formedix’s all-in-one cloud-based clinical metadata repository (CMDR) and… Read More

#News

#CRO #Data #Pharma #Pharmacovigilance

Outsourcing clinical research support – time to put safety first

Increasingly, pharma companies are looking for a one-stop-shop when outsourcing clinical research support. Outsourcing without focusing on safety, however, is turning out to be a costly decision for some companies, leading to mistakes and budget overrun. Natalia Vlcek, Pharmacovigilance Manager and EU QPPV at Arriello Group, contends that it is… Read More

#Exclusive Content #News

#Clinical trials #Covid-19 #Data #GlobalData #Immunology / Virology & Vaccines

Covid-19 vaccine and therapeutic trials show different trends

Since Covid-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was seen in the month of April 2020. There has since been a steady decrease in new clinical trial investigations, except for the months of December… Read More

#News #Trends & Analysis

#Data #Flow Cytometry

Bio-Rad introduces new dyes for flow cytometry

Bio-Rad has introduced three StarBright Dyes designed for flow cytometry applications. StarBright Violet 570, 670, and 710 Dyes offer improved brightness and precise excitation and emission spectra, making them suitable for use in multicolour flow cytometry panels. The line offers researchers a range of fluorescent nanoparticles conjugated to highly validated… Read More

#News

#Biopharmaceuticals #Data #Laboratory data

Laboratory data partnership

IDBS, innovator in Biopharmaceutical Lifecycle Management (BPLM), and Scitara, expert in laboratory IoT, have partnered to create a solution that will extend IDBS Polar BPLM’s laboratory data connectivity and instrument integration capabilities. This solution boosts the Polar workflow capabilities by addressing the challenge of sharing and digitalising laboratory data across… Read More

#News

#Cancer research #Data #Events #Immuno-oncology

GSK showcases advances in oncology at ASCO and EHA

GlaxoSmithKline (GSK) will present new data from key focus areas within its oncology portfolio at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the European Hematology Association (EHA) 2021 Virtual Congress (June 9-17). The company will present new data on its approved therapies, BLENREP… Read More

#News

#Data #Drug discovery #Drug screening #Screening #Whitepaper

Expertise on analysis of targeted protein degrader compounds

Small molecule drug discovery is expanding beyond traditional strategies focused on identifying compounds that inhibit or block the activity of proteins that cause disease, says Promega. A newer approach to small molecule drug discovery is to selectively target proteins for removal from the cell using degrader compounds, focussing on identifying… Read More

#News